Our technology is a patented and proprietary antigen-display nanoplatform based on Virus-Like Particles (VLPs). These are empty and non infectious structures mimicking real viruses and then capable to induce strong immune responses. We are able to incorporate pathology-associated antigens into VLPs generating chimeric nanoparticles (Ch-VLPs) that can be designed to specifically induce either humoral or cellular responses.

Advantages of VLPbio technology

• Biosafety: VLPs mimic real viruses but they are not infectious avoiding the issues related to pathogen inactivation and simplifying vaccines security tests
• High flexibility: Vaccines can be constituted by a formulation of different Ch-VLPs monocomponents displaying different antigens (cellular, humoral or both)
• Synthetic Design: Possibility to design synthetic antigenic consensus sequences covering different pathogen strains
• Compilance (DIVA)
• Low cost production
• Co-development of diagnostic tests